Clinical Trial Update: Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors [Phase 2]

View source ↗

Summary

A phase 2 clinical trial evaluating axitinib in metastatic renal cell carcinoma with favorable prognostic factors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: Kidney Cancer Research Bureau | Conditions: Carcinoma, Renal Cell, Clear Cell Renal Cell Carcinoma | Phase 2 | Status: COMPLETED